Proactiveinvestors USA & Canada TRACON Pharmaceuticals https://www.proactiveinvestors.com Proactiveinvestors USA & Canada TRACON Pharmaceuticals RSS feed en Fri, 05 Mar 2021 21:06:23 -0500 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) TRACON Pharmaceuticals ends FY2020 with $36.1M in cash and equivalents https://www.proactiveinvestors.com/companies/news/942376/tracon-pharmaceuticals-ends-fy2020-with-361m-in-cash-and-equivalents-942376.html Thu, 25 Feb 2021 21:40:00 -0500 https://www.proactiveinvestors.com/companies/news/942376/tracon-pharmaceuticals-ends-fy2020-with-361m-in-cash-and-equivalents-942376.html TRACON says cancer drug envafolimab gets priority review from Chinese regulators, according to corporate partners https://www.proactiveinvestors.com/companies/news/938875/tracon-says-cancer-drug-envafolimab-gets-priority-review-from-chinese-regulators-according-to-corporate-partners-938875.html Tue, 19 Jan 2021 15:05:00 -0500 https://www.proactiveinvestors.com/companies/news/938875/tracon-says-cancer-drug-envafolimab-gets-priority-review-from-chinese-regulators-according-to-corporate-partners-938875.html TRACON says envafolimab NDA wins acceptance for review by the NMPA in China https://www.proactiveinvestors.com/companies/news/937486/tracon-says-envafolimab-nda-wins-acceptance-for-review-by-the-nmpa-in-china-937486.html Wed, 30 Dec 2020 14:38:00 -0500 https://www.proactiveinvestors.com/companies/news/937486/tracon-says-envafolimab-nda-wins-acceptance-for-review-by-the-nmpa-in-china-937486.html TRACON Pharmaceuticals enters into securities purchase agreement with existing investor, with aggregate gross proceeds expected to be $5.0M https://www.proactiveinvestors.com/companies/news/937432/tracon-pharmaceuticals-enters-into-securities-purchase-agreement-with-existing-investor-with-aggregate-gross-proceeds-expected-to-be-50m-937432.html Tue, 29 Dec 2020 14:15:00 -0500 https://www.proactiveinvestors.com/companies/news/937432/tracon-pharmaceuticals-enters-into-securities-purchase-agreement-with-existing-investor-with-aggregate-gross-proceeds-expected-to-be-50m-937432.html TRACON Pharmaceuticals says it is looking to raise aggregate gross proceeds of $8.8 million from a registered direct share offering https://www.proactiveinvestors.com/companies/news/937191/tracon-pharmaceuticals-says-it-is-looking-to-raise-aggregate-gross-proceeds-of-88-million-from-aregistereddirect-share-offering-937191.html Tue, 22 Dec 2020 14:15:00 -0500 https://www.proactiveinvestors.com/companies/news/937191/tracon-pharmaceuticals-says-it-is-looking-to-raise-aggregate-gross-proceeds-of-88-million-from-aregistereddirect-share-offering-937191.html TRACON Pharmaceuticals says first patient dosed in ENVASARC registration trial to treat soft-tissue sarcoma cancer https://www.proactiveinvestors.com/companies/news/936250/tracon-pharmaceuticals-says-first-patient-dosed-in-envasarc-registration-trial-to-treat-soft-tissue-sarcoma-cancer-936250.html Thu, 10 Dec 2020 17:05:00 -0500 https://www.proactiveinvestors.com/companies/news/936250/tracon-pharmaceuticals-says-first-patient-dosed-in-envasarc-registration-trial-to-treat-soft-tissue-sarcoma-cancer-936250.html TRACON says publication of clinical data in Cancer Cell journal provides molecular insight into TRC102 https://www.proactiveinvestors.com/companies/news/934676/tracon-says-publication-of-clinical-data-in-cancer-cell-journal-provides-molecular-insight-into-trc102-934676.html Mon, 23 Nov 2020 15:44:00 -0500 https://www.proactiveinvestors.com/companies/news/934676/tracon-says-publication-of-clinical-data-in-cancer-cell-journal-provides-molecular-insight-into-trc102-934676.html TRACON's partners submit new drug application for approval of envafolimab to the NMPA in China https://www.proactiveinvestors.com/companies/news/934459/tracon-s-partners-submit-new-drug-application-for-approval-of-envafolimab-to-the-nmpa-in-china-934459.html Thu, 19 Nov 2020 18:44:00 -0500 https://www.proactiveinvestors.com/companies/news/934459/tracon-s-partners-submit-new-drug-application-for-approval-of-envafolimab-to-the-nmpa-in-china-934459.html TRACON says envafolimab NDA submitted for approval by its partners to the NMPA in China https://www.proactiveinvestors.com/companies/news/934095/tracon-says-envafolimab-nda-submitted-for-approval-by-its-partners-to-the-nmpa-in-china-934095.html Mon, 16 Nov 2020 18:31:00 -0500 https://www.proactiveinvestors.com/companies/news/934095/tracon-says-envafolimab-nda-submitted-for-approval-by-its-partners-to-the-nmpa-in-china-934095.html TRACON Pharmaceuticals strengthens its cash position in 3Q to fund operations into 2022 https://www.proactiveinvestors.com/companies/news/933636/tracon-pharmaceuticals-strengthens-its-cash-position-in-3q-to-fund-operations-into-2022-933636.html Tue, 10 Nov 2020 21:57:00 -0500 https://www.proactiveinvestors.com/companies/news/933636/tracon-pharmaceuticals-strengthens-its-cash-position-in-3q-to-fund-operations-into-2022-933636.html TRACON Pharmaceuticals driving the development of targeted therapies for cancer https://www.proactiveinvestors.com/companies/news/915153/tracon-pharmaceuticals-driving-the-development-of-targeted-therapies-for-cancer-915153.html Wed, 04 Nov 2020 12:00:00 -0500 https://www.proactiveinvestors.com/companies/news/915153/tracon-pharmaceuticals-driving-the-development-of-targeted-therapies-for-cancer-915153.html TRACON wins FDA Orphan Drug status for TRC102 in malignant glioma https://www.proactiveinvestors.com/companies/news/932382/tracon-wins-fda-orphan-drug-status-for-trc102-in-malignant-glioma-932382.html Mon, 26 Oct 2020 14:04:00 -0400 https://www.proactiveinvestors.com/companies/news/932382/tracon-wins-fda-orphan-drug-status-for-trc102-in-malignant-glioma-932382.html TRACON Pharmaceuticals highlights updated clinical data from the pivotal trial of envafolimab in MSI-H/dMMR cancer patients https://www.proactiveinvestors.com/companies/news/929582/tracon-pharmaceuticals-highlights-updated-clinical-data-from-the-pivotal-trial-of-envafolimab-in-msi-hdmmr-cancer-patients-929582.html Mon, 21 Sep 2020 14:45:00 -0400 https://www.proactiveinvestors.com/companies/news/929582/tracon-pharmaceuticals-highlights-updated-clinical-data-from-the-pivotal-trial-of-envafolimab-in-msi-hdmmr-cancer-patients-929582.html TRACON Pharmaceuticals launches private placement with multiple institutional health care focused funds to raise aggregate gross proceeds of approximately $5.0 million https://www.proactiveinvestors.com/companies/news/927887/tracon-pharmaceuticals-launches-private-placement-with-multiple-institutional-health-care-focused-funds-to-raise-aggregate-gross-proceeds-of-approximately-50-million-927887.html Mon, 31 Aug 2020 13:16:00 -0400 https://www.proactiveinvestors.com/companies/news/927887/tracon-pharmaceuticals-launches-private-placement-with-multiple-institutional-health-care-focused-funds-to-raise-aggregate-gross-proceeds-of-approximately-50-million-927887.html TRACON Pharmaceuticals approved by the FDA to begin sarcoma cancer therapy in humans https://www.proactiveinvestors.com/companies/news/926977/tracon-pharmaceuticals-approved-by-the-fda-to-begin-sarcoma-cancer-therapy-in-humans-926977.html Tue, 18 Aug 2020 20:02:00 -0400 https://www.proactiveinvestors.com/companies/news/926977/tracon-pharmaceuticals-approved-by-the-fda-to-begin-sarcoma-cancer-therapy-in-humans-926977.html TRACON Pharmaceuticals shares surge as it receives FDA nod for envafolimab trial in USA https://www.proactiveinvestors.com/companies/news/926838/tracon-pharmaceuticals-shares-surge-as-it-receives-fda-nod-for-envafolimab-trial-in-usa-926838.html Mon, 17 Aug 2020 13:25:00 -0400 https://www.proactiveinvestors.com/companies/news/926838/tracon-pharmaceuticals-shares-surge-as-it-receives-fda-nod-for-envafolimab-trial-in-usa-926838.html TRACON Pharmaceuticals - Proactive One2One Virtual Event https://www.proactiveinvestors.com/companies/news/926264/tracon-pharmaceuticals---proactive-one2one-virtual-event-926264.html Mon, 10 Aug 2020 13:10:00 -0400 https://www.proactiveinvestors.com/companies/news/926264/tracon-pharmaceuticals---proactive-one2one-virtual-event-926264.html NA Proactive news snapshot: Ipsidy, BioSig Technologies, Metalla Royalty & Streaming, Internet of Things, TRACON Pharmaceuticals UPDATE... https://www.proactiveinvestors.com/companies/news/926044/na-proactive-news-snapshotipsidy-biosig-technologies-metalla-royalty--streaming-internet-of-things-tracon-pharmaceuticals-update-926044.html Thu, 06 Aug 2020 21:00:00 -0400 https://www.proactiveinvestors.com/companies/news/926044/na-proactive-news-snapshotipsidy-biosig-technologies-metalla-royalty--streaming-internet-of-things-tracon-pharmaceuticals-update-926044.html TRACON posts 2Q results showing it has ample funds for ENVASARC trial to study envafolimab as a sarcoma treatment https://www.proactiveinvestors.com/companies/news/926028/tracon-posts-2q-results-showing-it-has-ample-funds-for-envasarc-trial-to-study-envafolimab-as-a-sarcoma-treatment-926028.html Thu, 06 Aug 2020 12:30:00 -0400 https://www.proactiveinvestors.com/companies/news/926028/tracon-posts-2q-results-showing-it-has-ample-funds-for-envasarc-trial-to-study-envafolimab-as-a-sarcoma-treatment-926028.html TRACON Pharmaceuticals files pivotal ENVASARC protocol with FDA for its sarcoma treatment drug https://www.proactiveinvestors.com/companies/news/924511/tracon-pharmaceuticals-files-pivotal-envasarc-protocol-with-fda-for-its-sarcoma-treatment-drug-924511.html Fri, 17 Jul 2020 15:25:00 -0400 https://www.proactiveinvestors.com/companies/news/924511/tracon-pharmaceuticals-files-pivotal-envasarc-protocol-with-fda-for-its-sarcoma-treatment-drug-924511.html TRACON Pharmaceuticals files ENVASARC protocol with FDA to study envafolimab as sarcoma treatment https://www.proactiveinvestors.com/companies/news/924400/tracon-pharmaceuticals-files-envasarc-protocol-with-fda-to-study-envafolimab-as-sarcoma-treatment-924400.html Thu, 16 Jul 2020 14:35:00 -0400 https://www.proactiveinvestors.com/companies/news/924400/tracon-pharmaceuticals-files-envasarc-protocol-with-fda-to-study-envafolimab-as-sarcoma-treatment-924400.html TRACON Pharmaceuticals to host key opinion leader webinar on envafolimab for the treatment of sarcoma on July 17 https://www.proactiveinvestors.com/companies/news/924047/tracon-pharmaceuticals-to-host-key-opinion-leader-webinar-on-envafolimab-for-the-treatment-of-sarcoma-on-july-17-924047.html Mon, 13 Jul 2020 13:40:00 -0400 https://www.proactiveinvestors.com/companies/news/924047/tracon-pharmaceuticals-to-host-key-opinion-leader-webinar-on-envafolimab-for-the-treatment-of-sarcoma-on-july-17-924047.html Biotech companies to dominate at Proactive One2One Virtual Investor Forum on June 23 https://www.proactiveinvestors.com/companies/news/922066/biotech-companies-to-dominate-at-proactive-one2one-virtual-investor-forum-on-june-23-922066.html Tue, 23 Jun 2020 13:20:00 -0400 https://www.proactiveinvestors.com/companies/news/922066/biotech-companies-to-dominate-at-proactive-one2one-virtual-investor-forum-on-june-23-922066.html Proactive virtual event to showcase four rising stars of the life sciences industry https://www.proactiveinvestors.com/companies/news/922480/proactive-virtual-event-to-showcase-four-rising-stars-of-the-life-sciences-industry-922480.html Mon, 22 Jun 2020 19:30:00 -0400 https://www.proactiveinvestors.com/companies/news/922480/proactive-virtual-event-to-showcase-four-rising-stars-of-the-life-sciences-industry-922480.html TRACON Pharmaceuticals says separate study buoys potential of envafolimab combination to treat sarcoma https://www.proactiveinvestors.com/companies/news/920734/tracon-pharmaceuticals-says-separate-study-buoys-potential-of-envafolimab-combination-to-treat-sarcoma-920734.html Fri, 29 May 2020 13:40:00 -0400 https://www.proactiveinvestors.com/companies/news/920734/tracon-pharmaceuticals-says-separate-study-buoys-potential-of-envafolimab-combination-to-treat-sarcoma-920734.html TRACON Pharmaceuticals looks forward to positive Phase 2 cancer trial data presentation on May 31 https://www.proactiveinvestors.com/companies/news/919635/tracon-pharmaceuticals-looks-forward-to-positive-phase-2-cancer-trial-data-presentation-on-may-31-919635.html Thu, 14 May 2020 17:10:00 -0400 https://www.proactiveinvestors.com/companies/news/919635/tracon-pharmaceuticals-looks-forward-to-positive-phase-2-cancer-trial-data-presentation-on-may-31-919635.html TRACON Pharmaceuticals to see envafolimab cancer treatment data presented at virtual oncology conference https://www.proactiveinvestors.com/companies/news/919630/tracon-pharmaceuticals-to-see-envafolimab-cancer-treatment-data-presented-at-virtual-oncology-conference-919630.html Thu, 14 May 2020 15:01:00 -0400 https://www.proactiveinvestors.com/companies/news/919630/tracon-pharmaceuticals-to-see-envafolimab-cancer-treatment-data-presented-at-virtual-oncology-conference-919630.html TRACON Pharmaceuticals believes its ENVASARC trial on envafolimab will enable a quick path to market https://www.proactiveinvestors.com/companies/news/919523/tracon-pharmaceuticals-believes-its-envasarc-trial-on-envafolimab-will-enable-a-quick-path-to-market-919523.html Wed, 13 May 2020 21:00:00 -0400 https://www.proactiveinvestors.com/companies/news/919523/tracon-pharmaceuticals-believes-its-envasarc-trial-on-envafolimab-will-enable-a-quick-path-to-market-919523.html TRACON Pharmaceuticals 'very pleased' with envafolimab pre-IND meeting with FDA https://www.proactiveinvestors.com/companies/news/919310/tracon-pharmaceuticals--very-pleased--with-envafolimab-pre-ind-meeting-with-fda-919310.html Mon, 11 May 2020 18:20:00 -0400 https://www.proactiveinvestors.com/companies/news/919310/tracon-pharmaceuticals--very-pleased--with-envafolimab-pre-ind-meeting-with-fda-919310.html TRACON Pharmaceuticals announces successful Type B meeting with FDA for Pivotal Study of Envafolimab in sarcoma https://www.proactiveinvestors.com/companies/news/919284/tracon-pharmaceuticals-announces-successful-type-b-meeting-with-fda-for-pivotal-study-of-envafolimab-in-sarcoma-919284.html Mon, 11 May 2020 14:25:00 -0400 https://www.proactiveinvestors.com/companies/news/919284/tracon-pharmaceuticals-announces-successful-type-b-meeting-with-fda-for-pivotal-study-of-envafolimab-in-sarcoma-919284.html